Watch the video and download the slides


Maintenance therapy for metastatic urothelial cancer

 

GU CONNECT expert, Prof. Sandy Srinivas discusses maintenance therapy for metastatic urothelial cancer, and in particular the practice-changing clinical trial JAVELIN 100.

My name is Sandy Srinivas. I’m a GU medical oncologist at Stanford in the United States.

 

It’s my pleasure to talk about a practice-changing phase 3 clinical trial, JAVELIN 100, which introduces the concept of maintenance therapy in first-line urothelial cancer.

 

By way of background, chemotherapy for urothelial cancer has been used for decades and it’s been the standard of care with life expectancy and overall survival ranging around 13 to 15 months.

 

Despite tremendous progress that’s been made with the incorporation of checkpoint inhibitors and immunotherapy in subsequent lines of therapy for urothelial cancer, integrating immunotherapy in the first-line space has been quite disappointing with the readout of many trials that have been negative to date.

 

The JAVELIN 100 trial had a unique design where patients were given standard of care chemotherapy with either cisplatin or carboplatin based. Following chemotherapy those who did not progress were then randomised to either avelumab at 10 mg per kilogram given every two weeks versus best supportive care. The primary endpoint of this trial was looking at overall survival.

 

What were the results?

 

The overall survival was astoundingly improved with a median overall survival of 21 months for the group that received the checkpoint inhibitor vs. 14 months for the best supportive care. This magnitude of benefit was even higher in the tumours that were enriched for PD-L1. Even more surprising was that the benefit was seen irrespective of whether patients received carboplatin or cisplatin, whether they received 4 cycles or 6 cycles, and irrespective of what the prior response to chemotherapy was, whether it was complete response, partial response or stable disease.

 

So here is my take and my conclusion of this trial. So rather than waiting for patients to progress off chemotherapy and then give them a checkpoint inhibitor as is approved today, I would change my practice and offer patients maintenance checkpoint inhibitor following response to chemotherapy.

 

It was my pleasure talking to you today on GU CONNECT and thank you so much for tuning in.

Sandy Srinivas specializes in urologic oncology and takes care of patients with prostate, bladder, kidney, testes, penile and adrenal cancers. She has practised in this field now for more than 20 years. She is the clinical research group leader for Urologic Program at Stanford and is a principal investigator on numerous trials in urologic Oncology and is the medical director for the in-patient hematology Oncology unit. She serves as the Vice-chair on the National Comprehensive Cancer Center (NCCN) panel for prostate cancer and has co-authored numerous publications and book chapters. She has received numerous teaching awards and is a nationally recognized expert in the field of Urologic Oncology.
Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Medical Grants from Bayer, AstraZeneca and Eisai Europe Limited.

Meet the experts

Other programmes of interest

Conference update
Oncology 
Oncogene-addicted NSCLC: Highlights from ASCO 2024

The latest non-small cell lung cancer data presented at ASCO

Experts
Prof. Nicolas Girard
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Upper lower GI cancer update ASCO 2024 Conference update
Oncology 
Upper and lower GI cancer update from ASCO 2024

GI oncologists review the latest data presented at ASCO 2024

Experts
Dr Samuel J Klempner, Dr Elizabeth Smyth, Prof. Jenny Seligmann, Dr Dominik Modest
  • clock 8 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Experts Knowledge Share Video
Oncology Hemato-oncology 
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Medical experts discuss the latest learnings from clinical practice

Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter
  • download Downloadable
    Resources
  • clock 76 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
Conference update

Episode

1

of 4

episode
Oncology 
ASCO 2024 lung cancer highlights

A conference update on lung cancer clinical trial data from ASCO

Experts
Prof. Mark Socinski
  • clock 4 MIN
  • calendar Jun 2024

Conference update

Episode

2

of 4

episode
Oncology 
ASCO 2024 breast cancer highlights

How could the data impact clinical practice?

Experts
Prof. Shaheenah Dawood
  • clock 3 MIN
  • calendar Jun 2024

Conference update

Episode

3

of 4

episode
Oncology 
ASCO 2024 HCC highlights

How could the latest clinical trial data impact the management of hepatocellular carcinoma?

Experts
Prof. Dr Peter R. Galle
  • clock 1 MIN
  • calendar Jun 2024